Koya Medical Announces TEAYS Full Study Results

Koya Medical, a healthcare company with a mission to transform venous and lymphatic treatments through novel, people-centric solutions, released the full results from the TEAYS (Treatment Effectiveness of a Non-Pneumatic Compression Device versus an Advanced Pneumatic Compression Device for Lower Extremity Lymphedema Swelling) clinical study. 
 
Study results were published in the Journal of Vascular Surgery (JVS). The data highlighted superior efficacy and improved quality of life for patients suffering from lower extremity lymphedema with Dayspring, a novel non-pneumatic compression device (NPCD), compared to advanced pneumatic compression devices (APCDs).
 
“The introduction of Dayspring represents a clinically differentiated and therapeutically distinct advancement in the treatment of lower extremity lymphedema,” said Dr. Michael Barfield, lead investigator and Associate Professor of Surgery at the University of Tennessee Health Science Center, Nashville, TN. “Patients participating in the TEAYS study expressed a strong preference for the Dayspring treatment over advanced pneumatic compression devices. The ability for patients to remain mobile while receiving effective treatment is a game-changer in improving adherence and overall quality of life.”
 
These results are consistent with prior studies’ findings associated with Dayspring for the treatment of lymphedema. 
 
Key findings included:
 
Significant improvements in the overall Lymphedema Quality of Life Questionnaire (LYMQOL) scores for Dayspring users, with a mean improvement of 1.01 compared to 0.17 for APCD users. Key functional sub-scores such as symptoms, appearance, and function also favored Dayspring.
 
Patients using Dayspring experienced a mean limb volume reduction of 369.9 mL, significantly greater than the 83.1 mL reduction observed in the APCD treatment arm.
 
Dayspring users demonstrated an adherence rate of 81%, significantly higher than the 56% adherence observed in the APCD group.
 
No device-related adverse events were reported for either treatment, highlighting the safety of Dayspring.